Search

Your search keyword '"Andrews, Miles C."' showing total 196 results
Start Over Author "Andrews, Miles C."
196 results on '"Andrews, Miles C."'

5. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

6. Multi-modal molecular programs regulate melanoma cell state

Author

Andrews, Miles C., Oba, Junna, Wu, Chang-Jiun, Zhu, Haifeng, Karpinets, Tatiana, Creasy, Caitlin A., Forget, Marie-Andrée, Yu, Xiaoxing, Song, Xingzhi, Mao, Xizeng, Robertson, A. Gordon, Romano, Gabriele, Li, Peng, Burton, Elizabeth M., Lu, Yiling, Sloane, Robert Szczepaniak, Wani, Khalida M., Rai, Kunal, Lazar, Alexander J., Haydu, Lauren E., Bustos, Matias A., Shen, Jianjun, Chen, Yueping, Morgan, Margaret B., Wargo, Jennifer A., Kwong, Lawrence N., Haymaker, Cara L., Grimm, Elizabeth A., Hwu, Patrick, Hoon, Dave S. B., Zhang, Jianhua, Gershenwald, Jeffrey E., Davies, Michael A., Futreal, P. Andrew, Bernatchez, Chantale, and Woodman, Scott E.

Published
2022
Full Text
View/download PDF

8. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Author

Andrews, Miles C., Duong, Connie P. M., Gopalakrishnan, Vancheswaran, Iebba, Valerio, Chen, Wei-Shen, Derosa, Lisa, and Khan, Md Abdul Wadud

Subjects
Microbiota (Symbiotic organisms) -- Health aspects, Immunotherapy -- Complications and side effects, Melanoma -- Development and progression -- Care and treatment, Biological sciences, Health
Abstract

Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and mechanisms of response and toxicity to CICB are needed. To address this, we profiled the blood, tumor and gut microbiome of 77 patients with advanced melanoma treated with CICB, with a high rate of any [greater than or equal to]grade 3 immune-related adverse events (49%) with parallel studies in pre-clinical models. Tumor-associated immune and genomic biomarkers of response to CICB were similar to those identified for ICB monotherapy, and toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Profiling of gut microbiota demonstrated a significantly higher abundance of Bacteroides intestinalis in patients with toxicity, with upregulation of mucosal IL-1[beta] in patient samples of colitis and in pre-clinical models. Together, these data offer potential new therapeutic angles for targeting toxicity to CICB. Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition., Author(s): Miles C. Andrews [sup.1] [sup.2] [sup.3] , Connie P. M. Duong [sup.4] [sup.5] [sup.6] , Vancheswaran Gopalakrishnan [sup.1] , Valerio Iebba [sup.4] [sup.5] , Wei-Shen Chen [sup.7] [sup.8] , [...]

Published
2021
Full Text
View/download PDF

10. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2023
Full Text
View/download PDF

11. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.

Author

Andrews, Miles C., Li, Gerald, Graf, Ryon P., Fisher, Virginia A., Mitchell, Jerry, Aboosaiedi, Ali, O'Rourke, Harriet, Shackleton, Mark, Iddawela, Mahesh, Oxnard, Geoffrey R., and Huang, Richard S.P.

Subjects
*IMMUNE checkpoint inhibitors, *MELANOMA, *OVERALL survival, *METASTASIS, *PROGRESSION-free survival
Abstract

PURPOSE: The choice of threshold and reliability of high tumor mutational burden (TMB) to predict outcomes and guide treatment choice for patients with metastatic melanoma receiving first-line immune checkpoint inhibitor (ICI) therapy in the real world is not well known. METHODS: Using a deidentified nationwide (US-based) melanoma clinicogenomic database, we identified a real-world cohort of patients with metastatic melanoma (N = 497) who received first-line monotherapy anti–PD-1 (n = 240) or dual anti–PD-1 and anti–CTLA-4 ICI (n = 257) and had a tissue-based comprehensive genomic profiling test TMB score. RESULTS: TMB-high (TMB-H; ≥10 mutations per megabase [muts/Mb], n = 352, 71%) was independently predictive of superior real-world progression-free survival and overall survival versus TMB-low (<10 mut/Mb, n = 145, 29%) in both mono ICI (hazard ratio [HR], 0.45 [95% CI, 0.32 to 0.63]; P <.001; HR, 0.61 [95% CI, 0.41 to 0.90]; P =.01, respectively) and dual ICI (HR, 0.67 [95% CI, 0.49 to 0.90]; P =.009; HR, 0.61 [95% CI, 0.42 to 0.88]; P =.007, respectively) patients. Dual ICI offered no significant advantage in BRAF wt patients and unexpectedly demonstrated greatest benefit in the TMB 10-19 mut/Mb group, identifying a TMB-very high (≥20 mut/Mb, n = 247, 50%) BRAF mut patient subgroup for whom mono ICI may be preferable. CONCLUSION: TMB-H predicts superior outcomes on ICI while coassessment of BRAF status and TMB may inform first-line regimen choice. Melanoma TMB predicts real-world ICI outcome but BRAF coassessment may better inform regimen choice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Author

Jacquelot, Nicolas, Yamazaki, Takahiro, Roberti, Maria P., Duong, Connie P. M., Andrews, Miles C., Verlingue, Loic, Ferrere, Gladys, Becharef, Sonia, Vétizou, Marie, Daillère, Romain, Messaoudene, Meriem, Enot, David P., Stoll, Gautier, Ugel, Stefano, Marigo, Ilaria, Foong Ngiow, Shin, Marabelle, Aurélien, Prevost-Blondel, Armelle, Gaudreau, Pierre-Olivier, Gopalakrishnan, Vancheswaran, Eggermont, Alexander M., Opolon, Paule, Klein, Christophe, Madonna, Gabriele, Ascierto, Paolo A., Sucker, Antje, Schadendorf, Dirk, Smyth, Mark J., Soria, Jean-Charles, Kroemer, Guido, Bronte, Vincenzo, Wargo, Jennifer, and Zitvogel, Laurence

Published
2019
Full Text
View/download PDF

14. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

15. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Author

Amaria, Rodabe N., Reddy, Sangeetha M., Tawbi, Hussein A., Davies, Michael A., Ross, Merrick I., Glitza, Isabella C., Cormier, Janice N., Lewis, Carol, Hwu, Wen-Jen, Hanna, Ehab, Diab, Adi, Wong, Michael K., Royal, Richard, Gross, Neil, Weber, Randal, Lai, Stephen Y., Ehlers, Richard, Blando, Jorge, Milton, Denái R., Woodman, Scott, Kageyama, Robin, Wells, Daniel K., Hwu, Patrick, Patel, Sapna P., Lucci, Anthony, Hessel, Amy, Lee, Jeffrey E., Gershenwald, Jeffrey, Simpson, Lauren, Burton, Elizabeth M., Posada, Liberty, Haydu, Lauren, Wang, Linghua, Zhang, Shaojun, Lazar, Alexander J., Hudgens, Courtney W., Gopalakrishnan, Vancheswaran, Reuben, Alexandre, Andrews, Miles C., Spencer, Christine N., Prieto, Victor, Sharma, Padmanee, Allison, James, Tetzlaff, Michael T., and Wargo, Jennifer A.

Published
2018
Full Text
View/download PDF

16. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Author

Mitra, Akash, Andrews, Miles C., Roh, Whijae, De Macedo, Marianna Petaccia, Hudgens, Courtney W., Carapeto, Fernando, Singh, Shailbala, Reuben, Alexandre, Wang, Feng, Mao, Xizeng, Song, Xingzhi, Wani, Khalida, Tippen, Samantha, Ng, Kwok-Shing, Schalck, Aislyn, Sakellariou-Thompson, Donald A., Chen, Eveline, Reddy, Sangeetha M., Spencer, Christine N., Wiesnoski, Diana, Little, Latasha D., Gumbs, Curtis, Cooper, Zachary A., Burton, Elizabeth M., Hwu, Patrick, Davies, Michael A., Zhang, Jianhua, Bernatchez, Chantale, Navin, Nicholas, Sharma, Padmanee, Allison, James P., Wargo, Jennifer A., Yee, Cassian, Tetzlaff, Michael T., Hwu, Wen-Jen, Lazar, Alexander J., and Futreal, P. Andrew

Published
2020
Full Text
View/download PDF

17. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

Author

Galvani, Elena, Mundra, Piyushkumar A., Valpione, Sara, Garcia-Martinez, Pablo, Smith, Matthew, Greenall, Jonathan, Thakur, Rohit, Helmink, Beth, Andrews, Miles C., Boon, Louis, Chester, Christopher, Gremel, Gabriela, Hogan, Kate, Mandal, Amit, Zeng, Kang, Banyard, Antonia, Ashton, Garry, Cook, Martin, Lorigan, Paul, Wargo, Jennifer A., Dhomen, Nathalie, and Marais, Richard

Published
2020
Full Text
View/download PDF

18. Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Author

Huang, Lu, primary, Malu, Shruti, primary, McKenzie, Jodi A., primary, Andrews, Miles C., primary, Talukder, Amjad H., primary, Tieu, Trang, primary, Karpinets, Tatiana, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Williams, Leila J., primary, Wang, Zhe, primary, Mbofung, Rina M., primary, Wang, Zhi-Qiang, primary, Davis, Richard Eric, primary, Lo, Roger S., primary, Wargo, Jennifer A., primary, Davies, Michael A., primary, Bernatchez, Chantale, primary, Heffernan, Timothy, primary, Amaria, Rodabe N., primary, Korkut, Anil, primary, Peng, Weiyi, primary, Roszik, Jason, primary, Lizée, Gregory, primary, Woodman, Scott E., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

21. Supplementary information from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Author

Huang, Lu, primary, Malu, Shruti, primary, McKenzie, Jodi A., primary, Andrews, Miles C., primary, Talukder, Amjad H., primary, Tieu, Trang, primary, Karpinets, Tatiana, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Williams, Leila J., primary, Wang, Zhe, primary, Mbofung, Rina M., primary, Wang, Zhi-Qiang, primary, Davis, Richard Eric, primary, Lo, Roger S., primary, Wargo, Jennifer A., primary, Davies, Michael A., primary, Bernatchez, Chantale, primary, Heffernan, Timothy, primary, Amaria, Rodabe N., primary, Korkut, Anil, primary, Peng, Weiyi, primary, Roszik, Jason, primary, Lizée, Gregory, primary, Woodman, Scott E., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Author

Huang, Lu, primary, Malu, Shruti, primary, McKenzie, Jodi A., primary, Andrews, Miles C., primary, Talukder, Amjad H., primary, Tieu, Trang, primary, Karpinets, Tatiana, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Williams, Leila J., primary, Wang, Zhe, primary, Mbofung, Rina M., primary, Wang, Zhi-Qiang, primary, Davis, Richard Eric, primary, Lo, Roger S., primary, Wargo, Jennifer A., primary, Davies, Michael A., primary, Bernatchez, Chantale, primary, Heffernan, Timothy, primary, Amaria, Rodabe N., primary, Korkut, Anil, primary, Peng, Weiyi, primary, Roszik, Jason, primary, Lizée, Gregory, primary, Woodman, Scott E., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

26. Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma

Author

Edwards, Jack M, primary, Andrews, Miles C, additional, Burridge, Hayley, additional, Smith, Robin, additional, Owens, Carole, additional, Edinger, Mark, additional, Pilkington, Katherine, additional, Desfrancois, Juliette, additional, Shackleton, Mark, additional, Senthi, Sashendra, additional, and van Zelm, Menno C, additional

Published
2023
Full Text
View/download PDF

29. Immune-related adverse events secondary to immunotherapy in oncology.

Author

Hui-Ling Yeoh, Freilich, Karen, Voskoboynik, Mark, Moore, Maggie, Andrews, Miles C., Shackleton, Mark, and Haydon, Andrew M.

Subjects
DRUG side effects, IMMUNOTHERAPY, ONCOLOGY, CANCER prognosis
Abstract

Background Immunotherapy has reshaped the prognoses for many cancers and is increasingly used in both metastatic and adjuvant settings. There is a high prevalence of immunotherapy side effects, or immune-related adverse events (irAEs), which can affect any organ. Some irAEs can cause permanent or prolonged morbidity and, in rare cases, may be fatal. irAEs can present with mild, non-specific symptoms, resulting in delays to identification and management. Objective We aim to provide a general overview of immunotherapy and irAEs, highlighting common clinical scenarios and general principles of management. Discussion Cancer immunotherapy toxicity is an important clinical problem that is increasingly relevant to general practice, where patients with adverse events may first present. Early diagnosis and timely intervention are important in limiting the severity and morbidity of these toxicities. The management of irAEs should follow treatment guidelines, in consultation with patients’ treating oncology teams. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation

Author

Wang, Minyu, primary, Zadeh, Soroor, additional, Pizzolla, Angela, additional, Thia, Kevin, additional, Gyorki, David E, additional, McArthur, Grant A, additional, Scolyer, Richard A, additional, Long, Georgina, additional, Wilmott, James S, additional, Andrews, Miles C, additional, Au-Yeung, George, additional, Weppler, Ali, additional, Sandhu, Shahneen, additional, Trapani, Joseph A, additional, Davis, Melissa J, additional, and Neeson, Paul Joseph, additional

Published
2022
Full Text
View/download PDF

31. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Author

Amaria, Rodabe N., Reddy, Sangeetha M., Tawbi, Hussein A., Davies, Michael A., Ross, Merrick I., Glitza, Isabella C., Cormier, Janice N., Lewis, Carol, Hwu, Wen-Jen, Hanna, Ehab, Diab, Adi, Wong, Michael K., Royal, Richard, Gross, Neil, Weber, Randal, Lai, Stephen Y., Ehlers, Richard, Blando, Jorge, Milton, Denái R., Woodman, Scott, Kageyama, Robin, Wells, Daniel K., Hwu, Patrick, Patel, Sapna P., Lucci, Anthony, Hessel, Amy, Lee, Jeffrey E., Gershenwald, Jeffrey, Simpson, Lauren, Burton, Elizabeth M., Posada, Liberty, Haydu, Lauren, Wang, Linghua, Zhang, Shaojun, Lazar, Alexander J., Hudgens, Courtney W., Gopalakrishnan, Vancheswaran, Reuben, Alexandre, Andrews, Miles C., Spencer, Christine N., Prieto, Victor, Sharma, Padmanee, Allison, James, Tetzlaff, Michael T., and Wargo, Jennifer A.

Published
2018
Full Text
View/download PDF

32. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Author

Amaria, Rodabe N., Reddy, Sangeetha M., Tawbi, Hussein A., Davies, Michael A., Ross, Merrick I., Glitza, Isabella C., Cormier, Janice N., Lewis, Carol, Hwu, Wen-Jen, Hanna, Ehab, Diab, Adi, Wong, Michael K., Royal, Richard, Gross, Neil, Weber, Randal, Lai, Stephen Y., Ehlers, Richard, Blando, Jorge, Milton, Denái R., Woodman, Scott, Kageyama, Robin, Wells, Daniel K., Hwu, Patrick, Patel, Sapna P., Lucci, Anthony, Hessel, Amy, Lee, Jeffrey E., Gershenwald, Jeffrey, Simpson, Lauren, Burton, Elizabeth M., Posada, Liberty, Haydu, Lauren, Wang, Linghua, Zhang, Shaojun, Lazar, Alexander J., Hudgens, Courtney W., Gopalakrishnan, Vancheswaran, Reuben, Alexandre, Andrews, Miles C., Spencer, Christine N., Prieto, Victor, Sharma, Padmanee, Allison, James, Tetzlaff, Michael T., and Wargo, Jennifer A.

Published
2018
Full Text
View/download PDF

33. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Author

Spencer, Christine N., primary, McQuade, Jennifer L., additional, Gopalakrishnan, Vancheswaran, additional, McCulloch, John A., additional, Vetizou, Marie, additional, Cogdill, Alexandria P., additional, Khan, Md A. Wadud, additional, Zhang, Xiaotao, additional, White, Michael G., additional, Peterson, Christine B., additional, Wong, Matthew C., additional, Morad, Golnaz, additional, Rodgers, Theresa, additional, Badger, Jonathan H., additional, Helmink, Beth A., additional, Andrews, Miles C., additional, Rodrigues, Richard R., additional, Morgun, Andrey, additional, Kim, Young S., additional, Roszik, Jason, additional, Hoffman, Kristi L., additional, Zheng, Jiali, additional, Zhou, Yifan, additional, Medik, Yusra B., additional, Kahn, Laura M., additional, Johnson, Sarah, additional, Hudgens, Courtney W., additional, Wani, Khalida, additional, Gaudreau, Pierre-Olivier, additional, Harris, Angela L., additional, Jamal, Mohamed A., additional, Baruch, Erez N., additional, Perez-Guijarro, Eva, additional, Day, Chi-Ping, additional, Merlino, Glenn, additional, Pazdrak, Barbara, additional, Lochmann, Brooke S., additional, Szczepaniak-Sloane, Robert A., additional, Arora, Reetakshi, additional, Anderson, Jaime, additional, Zobniw, Chrystia M., additional, Posada, Eliza, additional, Sirmans, Elizabeth, additional, Simon, Julie, additional, Haydu, Lauren E., additional, Burton, Elizabeth M., additional, Wang, Linghua, additional, Dang, Minghao, additional, Clise-Dwyer, Karen, additional, Schneider, Sarah, additional, Chapman, Thomas, additional, Anang, Nana-Ama A. S., additional, Duncan, Sheila, additional, Toker, Joseph, additional, Malke, Jared C., additional, Glitza, Isabella C., additional, Amaria, Rodabe N., additional, Tawbi, Hussein A., additional, Diab, Adi, additional, Wong, Michael K., additional, Patel, Sapna P., additional, Woodman, Scott E., additional, Davies, Michael A., additional, Ross, Merrick I., additional, Gershenwald, Jeffrey E., additional, Lee, Jeffrey E., additional, Hwu, Patrick, additional, Jensen, Vanessa, additional, Samuels, Yardena, additional, Straussman, Ravid, additional, Ajami, Nadim J., additional, Nelson, Kelly C., additional, Nezi, Luigi, additional, Petrosino, Joseph F., additional, Futreal, P. Andrew, additional, Lazar, Alexander J., additional, Hu, Jianhua, additional, Jenq, Robert R., additional, Tetzlaff, Michael T., additional, Yan, Yan, additional, Garrett, Wendy S., additional, Huttenhower, Curtis, additional, Sharma, Padmanee, additional, Watowich, Stephanie S., additional, Allison, James P., additional, Cohen, Lorenzo, additional, Trinchieri, Giorgio, additional, Daniel, Carrie R., additional, and Wargo, Jennifer A., additional

Published
2021
Full Text
View/download PDF

34. Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

Author

Sloane, Robert A. Szczepaniak, primary, White, Michael G., additional, Witt, Russell G., additional, Banerjee, Anik, additional, Davies, Michael A., additional, Han, Guangchun, additional, Burton, Elizabeth, additional, Ajami, Nadim, additional, Simon, Julie M., additional, Bernatchez, Chantale, additional, Haydu, Lauren E., additional, Tawbi, Hussein A., additional, Gershenwald, Jeffrey E., additional, Keung, Emily, additional, Ross, Merrick, additional, McQuade, Jennifer, additional, Amaria, Rodabe N., additional, Wani, Khalida, additional, Lazar, Alexander J., additional, Woodman, Scott E., additional, Wang, Linghua, additional, Andrews, Miles C., additional, and Wargo, Jennifer A., additional

Published
2021
Full Text
View/download PDF

35. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma

Author

White, Michael G., primary, Szczepaniak Sloane, Robert, additional, Witt, Russell G., additional, Reuben, Alexandre, additional, Gaudreau, Pierre Olivier, additional, Andrews, Miles C., additional, Feng, Ningping, additional, Johnson, Sarah, additional, Class, Caleb A., additional, Bristow, Christopher, additional, Wani, Khalida, additional, Hudgens, Courtney, additional, Nezi, Luigi, additional, Manzo, Teresa, additional, De Macedo, Mariana Pettaccia, additional, Hu, Jianhua, additional, Davis, Richard, additional, Jiang, Hong, additional, Prieto, Peter, additional, Burton, Elizabeth, additional, Hwu, Patrick, additional, Tawbi, Hussein, additional, Gershenwald, Jeffrey, additional, Lazar, Alexander J., additional, Tetzlaff, Michael T., additional, Overwijk, Willem, additional, Woodman, Scott E, additional, Cooper, Zachary A., additional, Marszalek, Joseph R., additional, Davies, Michael A., additional, Heffernan, Timothy P., additional, and Wargo, Jennifer A., additional

Published
2021
Full Text
View/download PDF

37. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Amaria, Rodabe N, primary, Menzies, Alexander M, additional, Burton, Elizabeth M, additional, Scolyer, Richard A, additional, Tetzlaff, Michael T, additional, Antdbacka, Robert, additional, Ariyan, Charlotte, additional, Bassett, Roland, additional, Carter, Brett, additional, Daud, Adil, additional, Faries, Mark, additional, Fecher, Leslie A, additional, Flaherty, Keith T, additional, Gershenwald, Jeffrey E, additional, Hamid, Omid, additional, Hong, Angela, additional, Kirkwood, John M, additional, Lo, Serigne, additional, Margolin, Kim, additional, Messina, Jane, additional, Postow, Michael A, additional, Rizos, Helen, additional, Ross, Merrick I, additional, Rozeman, Elisa A, additional, Saw, Robyn P M, additional, Sondak, Vernon, additional, Sullivan, Ryan J, additional, Taube, Janis M, additional, Thompson, John F, additional, van de Wiel, Bart A, additional, Eggermont, Alexander M, additional, Davies, Michael A, additional, Ascierto, Paolo A, additional, Spillane, Andrew J, additional, van Akkooi, Alexander C J, additional, Wargo, Jennifer A, additional, Blank, Christian U, additional, Tawbi, Hussein A, additional, Long, Georgina V, additional, Andrews, Miles C, additional, Berry, Donald A, additional, Block, Matthew S, additional, Boland, Genevieve M, additional, Bollin, Kathryn B, additional, Carlino, Matteo S, additional, Carvajal, Richard D, additional, Cohen, Jonathan, additional, Davar, Diwakar, additional, Delman, Keith A, additional, Dummer, Reinhard, additional, Farwell, Michael D, additional, Fisher, David E, additional, Fusi, Alberto, additional, Glitza, Isabella C, additional, de Gruijl, Tanja D, additional, Gyorki, David E, additional, Hauschild, Axel, additional, Hieken, Tina J, additional, Larkin, James, additional, Lawson, David H, additional, Lebbe, Celeste, additional, Lee, Jeffrey E, additional, Lowe, Michael C, additional, Luke, Jason J, additional, McArthur, Grant A, additional, McDermott, David F, additional, McQuade, Jennifer L, additional, Mitchell, Tara C, additional, Petrella, Teresa M, additional, Prieto, Peter A, additional, Puzanov, Igor, additional, Robert, Caroline, additional, Salama, April K, additional, Sandhu, Shaneen, additional, Schadendorf, Dirk, additional, Shoushtari, Alexander N, additional, Sosman, Jeffrey A, additional, Swetter, Susan M, additional, Tanabe, Ken K, additional, Turajlic, Samra, additional, Tyler, Douglas S, additional, Woodman, Scott E, additional, Wright, Frances C, additional, and Zager, Jonathan S, additional

Published
2019
Full Text
View/download PDF

38. Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors

Author

Spencer, Christine N., primary, Gopalakrishnan, Vancheswaran, additional, McQuade, Jennifer, additional, Andrews, Miles C., additional, Helmink, Beth, additional, Khan, M.A. Wadud, additional, Sirmans, Elizabeth, additional, Haydu, Lauren, additional, Cogdill, Alexandria, additional, Burton, Elizabeth, additional, Amaria, Rodabe, additional, Patel, Sapna, additional, Glitza, Isabella, additional, Davies, MIchael, additional, Posada, Eliza, additional, Hwu, Wen-Jen, additional, Diab, Adi, additional, Nelson, Kelly, additional, Tawbi, Hussein, additional, Wong, Michael, additional, Jenq, Robert R., additional, Cohen, Lorenzo, additional, Daniel-MacDougall, Carrie, additional, and Wargo, Jennifer A., additional

Published
2019
Full Text
View/download PDF

39. Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy

Author

Mitra, Akash, primary, Andrews, Miles C., additional, Roh, Whijae, additional, Macedo, Mariana P. de, additional, Reuben, Alexandre, additional, Carapeto, Fernando, additional, Wang, Feng, additional, Reddy, Sangeetha M., additional, Wani, Khalida, additional, Spencer, Christine, additional, Miller, John, additional, Schalck, Aislyn, additional, Little, Latasha D., additional, Sakellariou-Thompson, Donald A., additional, Gumbs, Curtis, additional, Hwu, Wen-Jen, additional, Bernatchez, Chantale, additional, Zhang, Jianhua, additional, Hwu, Patrick, additional, Navin, Nicholas, additional, Sharma, Padmanee, additional, Allison, James P., additional, Wargo, Jennifer, additional, Lazar, Alexander J., additional, and Futreal, Philip A., additional

Published
2019
Full Text
View/download PDF

42. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Author

Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia, University of Zurich, and Wellbrock, Claudia

Subjects
MITF, Genotype, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, 10177 Dermatology Clinic, AXL, 610 Medicine & health, Drug Tolerance, Endothelin, BRAF, Phenotype, 1313 Molecular Medicine, Journal Article, melanoma, Humans, endothelin, neoplasms, Melanoma, Research Articles, Research Article, Cancer, Skin
Abstract

Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a "MITF-high" phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulations of the de novo resistance "AXL-high" phenotype. > 50% of melanomas progress with enriched "AXL-high" populations, and because AXL is linked to de-differentiation and invasiveness avoiding an "AXL-high relapse" is desirable. We discovered that phenotype heterogeneity is supported during the response phase of BRAF inhibitor therapy due to MITF-induced expression of endothelin 1 (EDN1). EDN1 expression is enhanced in tumours of patients on treatment and confers drug resistance through ERK re-activation in a paracrine manner. Most importantly, EDN1 not only supports MITF-high populations through the endothelin receptor B (EDNRB), but also AXL-high populations through EDNRA, making it a master regulator of phenotype heterogeneity. Endothelin receptor antagonists suppress AXL-high-expressing cells and sensitize to BRAF inhibition, suggesting that targeting EDN1 signalling could improve BRAF inhibitor responses without selecting for AXL-high cells.

Published
2017

43. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Author

Huang, Lu, primary, Malu, Shruti, additional, McKenzie, Jodi A., additional, Andrews, Miles C., additional, Talukder, Amjad H., additional, Tieu, Trang, additional, Karpinets, Tatiana, additional, Haymaker, Cara, additional, Forget, Marie-Andrée, additional, Williams, Leila J., additional, Wang, Zhe, additional, Mbofung, Rina M., additional, Wang, Zhi-Qiang, additional, Davis, Richard Eric, additional, Lo, Roger S., additional, Wargo, Jennifer A., additional, Davies, Michael A., additional, Bernatchez, Chantale, additional, Heffernan, Timothy, additional, Amaria, Rodabe N., additional, Korkut, Anil, additional, Peng, Weiyi, additional, Roszik, Jason, additional, Lizée, Gregory, additional, Woodman, Scott E., additional, and Hwu, Patrick, additional

Published
2018
Full Text
View/download PDF

45. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma

Author

Da Gama Duarte, Jessica, primary, Parakh, Sagun, additional, Andrews, Miles C., additional, Woods, Katherine, additional, Pasam, Anupama, additional, Tutuka, Candani, additional, Ostrouska, Simone, additional, Blackburn, Jonathan M., additional, Behren, Andreas, additional, and Cebon, Jonathan, additional

Published
2018
Full Text
View/download PDF

47. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Author

Amaria, Rodabe N, primary, Prieto, Peter A, additional, Tetzlaff, Michael T, additional, Reuben, Alexandre, additional, Andrews, Miles C, additional, Ross, Merrick I, additional, Glitza, Isabella C, additional, Cormier, Janice, additional, Hwu, Wen-Jen, additional, Tawbi, Hussein A, additional, Patel, Sapna P, additional, Lee, Jeffrey E, additional, Gershenwald, Jeffrey E, additional, Spencer, Christine N, additional, Gopalakrishnan, Vancheswaran, additional, Bassett, Roland, additional, Simpson, Lauren, additional, Mouton, Rosalind, additional, Hudgens, Courtney W, additional, Zhao, Li, additional, Zhu, Haifeng, additional, Cooper, Zachary A, additional, Wani, Khalida, additional, Lazar, Alexander, additional, Hwu, Patrick, additional, Diab, Adi, additional, Wong, Michael K, additional, McQuade, Jennifer L, additional, Royal, Richard, additional, Lucci, Anthony, additional, Burton, Elizabeth M, additional, Reddy, Sangeetha, additional, Sharma, Padmanee, additional, Allison, James, additional, Futreal, Phillip A, additional, Woodman, Scott E, additional, Davies, Michael A, additional, and Wargo, Jennifer A, additional

Published
2018
Full Text
View/download PDF

49. Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response

Author

Woodman, Scott E., primary, Prieto, Peter, additional, Andrews, Miles C., additional, Amaria, Rodabe N., additional, Tetzlaff, Michael, additional, Diab, Adi, additional, Patel, Sapna P., additional, Wen-Jen, Hwu, additional, Glitza, Isabella, additional, Tawbi, Hussein, additional, Hwu, Patrick, additional, Cormier, Janice, additional, Lucci, Anthony, additional, Royal, Richard, additional, Lee, Jeffrey, additional, Bassett, Roland, additional, Simpson, Lauren, additional, Burton, Elizabeth, additional, Zhao, Li, additional, Grimm, Elizabeth, additional, Reuben, Alexandre, additional, Spencer, Christine, additional, Oba, Junna, additional, Ross, Merrick, additional, Gershenwald, Jeffrey, additional, Davies, Michael, additional, and Wargo, Jennifer A., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results